Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
PFE | NYSE | USD | Real-time | |
PFE | CBOE Canada | CAD | Real-time | |
PFE | Mexico | MXN | Delayed | |
1PFE | Milan | EUR | Real-time | |
PFE | Hamburg | EUR | Delayed | |
PFE | TradeGate | EUR | Delayed | |
PFE | Frankfurt | EUR | Delayed | |
PFE | Xetra | EUR | Delayed | |
PFE | Santiago | USD | Delayed | |
PFEm | Buenos Aires | ARS | Delayed | |
PFIZ34 | B3 | BRL | Delayed | |
PFE | Vienna | EUR | Real-time | |
PFE | Ukraine | UAH | Delayed | |
PFE_KZTQBD | KASE | USD | Delayed | |
PFE_KZ | KASE | USD | Delayed | |
PFE | Colombia | COP | Delayed | |
PFE | Lima | USD | Delayed |
Pfizer Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported sales was USD 1,910 million compared to USD 2,217 million a year ago. Revenue was USD 14,249 million compared to USD 24,290 million a year ago. Net loss was USD 3,369 million compared to net income of USD 4,995 million a year ago. Basic loss per share from continuing operations was USD 0.59 compared to basic earnings per share from continuing operations of USD 0.89 a year ago. Diluted loss per share from continuing operations was USD 0.59 compared to diluted earnings per share from continuing operations of USD 0.87 a year ago. Basic loss per share was USD 0.6 compared to basic earnings per share of USD 0.89 a year ago. Diluted loss per share was USD 0.6 compared to diluted earnings per share of USD 0.87 a year ago.For the full year, revenue was USD 58,496 million compared to USD 100,330 million a year ago. Net income was USD 2,119 million compared to USD 31,372 million a year ago. Basic earnings per share from continuing operations was USD 0.38 compared to USD 5.59 a year ago. Diluted earnings per share from continuing operations was USD 0.37 compared to USD 5.47 a year ago. Basic earnings per share was USD 0.38 compared to USD 5.59 a year ago. Diluted earnings per share was USD 0.37 compared to USD 5.47 a year ago.
Period Ending: | Dec 31, 2023 | Oct 01, 2023 | Jul 02, 2023 | Apr 02, 2023 |
---|---|---|---|---|
Total Revenue | 14249 | 13232 | 12734 | 18282 |
Gross Profit | 6984 | 9927 | 9802 | 13535 |
Operating Income | -1219 | 2954 | 2657 | 6662 |
Net Income | -3369 | -2382 | 2327 | 5543 |
Period Ending: | Dec 31, 2023 | Oct 01, 2023 | Jul 02, 2023 | Apr 02, 2023 |
---|---|---|---|---|
Total Assets | 215021 | 220168 | 195617 | |
Total Liabilities | 117817 | 120875 | 94381 | |
Total Equity | 97204 | 97204 | 99293 | 101236 |
Period Ending: | Dec 31, 2023 | Oct 01, 2023 | Jul 02, 2023 | Apr 02, 2023 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | -1208 | 1212 | ||
Cash From Investing Activities | -25485 | 3315 | ||
Cash From Financing Activities | 27174 | -2771 | ||
Net Change in Cash | 475 | 1754 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review